It really is believed to improve the heart’s ability to contract by promoting the repair of tissue damage resulting from heart disease or injury. Existing medicines for heart failure try to change the workload of the heart primarily, than promote ventricular repair rather. Acorda submitted an IND for GGF2 as a therapy for heart failure, predicated on extensive research simply by the ongoing firm and both independent and collaborative academic centers. Acorda can be continuing preclinical research of potential neurology indications for GGF2 and other neuregulin growth factors.. Acorda Therapeutics to initiate Stage 1 clinical trial of GGF2 for heart failing in mid-2010 Acorda Therapeutics, Inc.Modeling was performed with the use of the PROC MIXED process in SAS software, edition 9 . In subsequent analyses, the model was altered to displace the carrier variable with a continuous variable add up to 0 for noncarriers, 1 for heterozygotes, and 2 for homozygotes; this model was used only to test for linear pattern associated with allele dosage. The model was also altered with two indicator variables to assess variations between non-carriers and heterozygotes and between noncarriers and homozygotes; this model was useful for all other reported results. These analyses had been prespecified but were regarded as exploratory, given the tiny number of homozygotes. Baseline characteristics and the ones recorded during follow-up were compared among groups by using the two-sample t-check, the analysis-of-variance F-test, or the Pearson chi-square test.).